Kimberly J Jasmer1, Lucas T Woods2, Kevin Muñoz Forti2, Adam L Martin2, Jean M Camden2, Marco Colonna3, Gary A Weisman2. 1. Department of Biochemistry and Christopher S. Bond Life Sciences Center, University of Missouri, 1201 Rollins St., Columbia, MO, 65211-7310, USA. Electronic address: JasmerK@missouri.edu. 2. Department of Biochemistry and Christopher S. Bond Life Sciences Center, University of Missouri, 1201 Rollins St., Columbia, MO, 65211-7310, USA. 3. Department of Pathology and Immunology, Washington University School of Medicine, 660 S. Euclid Ave., St. Louis, MO, 63110, USA.
Abstract
OBJECTIVE: Sjögren's syndrome (SS) is a chronic autoimmune exocrinopathy characterized by lymphocytic infiltration of the salivary and lacrimal glands and decreased saliva and tear production. Previous studies indicate that the G protein-coupled P2Y2 nucleotide receptor (P2Y2R) is upregulated in numerous models of salivary gland inflammation (i.e., sialadenitis), where it has been implicated as a key mediator of chronic inflammation. Here, we evaluate both systemic and localized P2Y2R antagonism as a means to resolve sialadenitis in the NOD.H-2h4,IFNγ-/-,CD28-/- (NOD.H-2h4 DKO) mouse model of SS. DESIGN: Female 4.5 month old NOD.H-2h4 DKO mice received daily intraperitoneal injections for 10 days of the selective P2Y2R antagonist, AR-C118925, or vehicle-only control. Single-dose localized intraglandular antagonist delivery into the Wharton's duct was also evaluated. Carbachol-induced saliva was measured and then submandibular glands (SMGs) were isolated and either fixed and paraffin-embedded for H&E staining, homogenized for RNA isolation or dissociated for flow cytometry analysis. RESULTS: Intraperitoneal injection, but not localized intraglandular administration, of AR-C118925 significantly enhanced carbachol-induced salivation and reduced lymphocytic foci and immune cell markers in SMGs of 5 month old NOD.H-2h4 DKO mice, compared to vehicle-injected control mice. We found that B cells represent the primary immune cell population in inflamed SMGs of NOD.H-2h4 DKO mice that express elevated levels of P2Y2R compared to C57BL/6 control mice. We further demonstrate a role for P2Y2Rs in mediating B cell migration and the release of IgM. CONCLUSION: Our findings suggest that the P2Y2R represents a novel therapeutic target for the treatment of Sjögren's syndrome.
OBJECTIVE: Sjögren's syndrome (SS) is a chronic autoimmune exocrinopathy characterized by lymphocytic infiltration of the salivary and lacrimal glands and decreased saliva and tear production. Previous studies indicate that the G protein-coupled P2Y2 nucleotide receptor (P2Y2R) is upregulated in numerous models of salivary gland inflammation (i.e., sialadenitis), where it has been implicated as a key mediator of chronic inflammation. Here, we evaluate both systemic and localized P2Y2R antagonism as a means to resolve sialadenitis in the NOD.H-2h4,IFNγ-/-,CD28-/- (NOD.H-2h4 DKO) mouse model of SS. DESIGN: Female 4.5 month old NOD.H-2h4 DKO mice received daily intraperitoneal injections for 10 days of the selective P2Y2R antagonist, AR-C118925, or vehicle-only control. Single-dose localized intraglandular antagonist delivery into the Wharton's duct was also evaluated. Carbachol-induced saliva was measured and then submandibular glands (SMGs) were isolated and either fixed and paraffin-embedded for H&E staining, homogenized for RNA isolation or dissociated for flow cytometry analysis. RESULTS: Intraperitoneal injection, but not localized intraglandular administration, of AR-C118925 significantly enhanced carbachol-induced salivation and reduced lymphocytic foci and immune cell markers in SMGs of 5 month old NOD.H-2h4 DKO mice, compared to vehicle-injected control mice. We found that B cells represent the primary immune cell population in inflamed SMGs of NOD.H-2h4 DKO mice that express elevated levels of P2Y2R compared to C57BL/6 control mice. We further demonstrate a role for P2Y2Rs in mediating B cell migration and the release of IgM. CONCLUSION: Our findings suggest that the P2Y2R represents a novel therapeutic target for the treatment of Sjögren's syndrome.
Authors: Sriparna Bagchi; Zhongji Liao; Fernando A Gonzalez; Nataliya E Chorna; Cheikh I Seye; Gary A Weisman; Laurie Erb Journal: J Biol Chem Date: 2005-09-26 Impact factor: 5.157
Authors: Ann M Ratchford; Olga J Baker; Jean M Camden; Shivaji Rikka; Michael J Petris; Cheikh I Seye; Laurie Erb; Gary A Weisman Journal: J Biol Chem Date: 2010-01-11 Impact factor: 5.157
Authors: Hind Letaief; Cédric Lukas; Thomas Barnetche; Cécile Gaujoux-Viala; Bernard Combe; Jacques Morel Journal: Joint Bone Spine Date: 2017-06-30 Impact factor: 4.929
Authors: N Riteau; L Baron; B Villeret; N Guillou; F Savigny; B Ryffel; F Rassendren; M Le Bert; A Gombault; I Couillin Journal: Cell Death Dis Date: 2012-10-11 Impact factor: 8.469
Authors: Mahmoud G Khalafalla; Lucas T Woods; Kimberly J Jasmer; Kevin Muñoz Forti; Jean M Camden; Janicke L Jensen; Kirsten H Limesand; Hilde K Galtung; Gary A Weisman Journal: Front Pharmacol Date: 2020-03-13 Impact factor: 5.810
Authors: Kimberly J Jasmer; Kevin Muñoz Forti; Lucas T Woods; Seunghee Cha; Gary A Weisman Journal: Purinergic Signal Date: 2022-10-11 Impact factor: 3.950
Authors: Lili Li; Kimberly J Jasmer; Jean M Camden; Lucas T Woods; Adam L Martin; Yong Yang; Maria Layton; Michael J Petris; Olga J Baker; Gary A Weisman; Carisa K Petris Journal: Invest Ophthalmol Vis Sci Date: 2022-06-01 Impact factor: 4.925